retatrutide and nad+ together Diagram showing the mechanism of action of Retatrutide 12mg - Peptas

Saxenda vs Retatrutide: Titration Speed and Tolerability Compared At a glance Drug class (Saxenda) / GLP-1 receptor agonist, daily subcutaneous injection Drug class (Retatrutide) / GIP + GLP-1 + glucagon triple agonist, weekly subcutaneous injection Saxenda maintenance dose / 3.0 mg daily (fixed) Retatrutide Phase 2 top dose / 12 mg weekly (weight-adaptive titration) Saxenda titration duration / 5 weeks (0.6 mg up to 3.0 mg) Retatrutide titration duration / approximately 24 weeks across multiple escalation steps Mean weight loss at trial end (Saxenda) / 8.0% at 56 weeks in SCALE (N=3,731) Mean weight loss at trial end (Retatrutide) / up to 24.2% at 48 weeks in Phase 2 (N=338) Saxenda GI discontinuation rate / approximately 9.8% in SCALE Retatrutide regulatory status / Phase 3 trials ongoing

Comparison with other GLP-1s As compared to other GLP-1RAs, orforglipron is a direct and orally active small molecule, rather than a peptide

Use code FIRST10 for 10% OFF at checkout Save more with box purchases

Rapid injection forces medication into the tissue faster than it can accommodate, creating a pressurized pocket that causes pain and can push medication back out through the needle track

After its used or the medication has expired, discard the pen in an FDA-cleared sharps container

Spontaneous bilateral BGH occurs rarely, with only 60 instances having been reported in the literature [3]